Ultragenyx Pharmaceutical | RARE - Interest Expense On Debt

Stock Price
25.00
Daily Change
-0.80 -3.10%
Monthly
1.96%
Yearly
-29.80%
Q2 Forecast
24.50

Ultragenyx Pharmaceutical reported $21M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Esperion Therapeutics USD 22.64M 585K Dec/2025
Immunic 197K 222K Dec/2025
Insmed USD 20.08M 517K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Kyowa Hakko Kirin JPY 2.27B 1.84B Mar/2026
MacroGenics USD 3.34M 2.54M Sep/2025
Moderna USD 11.49B 36B Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xoma USD 3.4M 150K Jun/2024